Cargando…

Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease

PURPOSE OF REVIEW: Patients with non-alcoholic fatty liver disease (NAFLD), often considered as the hepatic manifestation of the metabolic syndrome, represent a population at high cardiovascular risk and frequently suffer from atherogenic dyslipidemia. This article reviews the pathogenic interrelati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martin, Anna, Lang, Sonja, Goeser, Tobias, Demir, Münevver, Steffen, Hans-Michael, Kasper, Philipp
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Statin Drugs (R. Ceska, Section Editor)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9236990/ https://www.ncbi.nlm.nih.gov/pubmed/35507279 http://dx.doi.org/10.1007/s11883-022-01028-4

Ejemplares similares

The Knowns and Unknowns of Contemporary Statin Therapy for Familial Hypercholesterolemia
por: Pang, Jing, et al.
Publicado: (2020)

LDL Apheresis and Lp (a) Apheresis: A Clinician’s Perspective
por: Kayikcioglu, Meral
Publicado: (2021)

Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel?
por: Fruchart, Jean-Charles, et al.
Publicado: (2021)

Lipid Lowering Drugs: Present Status and Future Developments
por: Ruscica, Massimiliano, et al.
Publicado: (2021)

Remnants, LDL, and the Quantification of Lipoprotein-Associated Risk in Atherosclerotic Cardiovascular Disease
por: Packard, Chris J.
Publicado: (2022)

Current Approach to the Diagnosis and Treatment of Heterozygote and Homozygous FH Children and Adolescents
por: Cohen, Hofit, et al.
Publicado: (2021)

The Role of High-Density Lipoprotein Cholesterol in 2022
por: Sirtori, Cesare R., et al.
Publicado: (2022)

PCSK9 Inhibitors in Real-world Practice: Analysis of Data from 314 Patients and 2 Years of Experience in a Center of Preventive Cardiology
por: Altschmiedová, Tereza, et al.
Publicado: (2022)

An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial
por: Lorgelly, Paula K., et al.
Publicado: (2010)

Screening strategies for non-alcoholic fatty liver disease: a holistic approach is needed
por: Kasper, Philipp, et al.
Publicado: (2023)

A Review of the Rationale for Additional Therapeutic Interventions to Attain Lower LDL-C When Statin Therapy Is Not Enough
por: Shanes, Jeffrey G.
Publicado: (2011)

Statin Intolerance: the Clinician’s Perspective
por: Stulc, Tomáš, et al.
Publicado: (2015)

Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence
por: Lee, Matthew M. Y., et al.
Publicado: (2019)

Role of Statin Therapy in Primary Prevention of Cardiovascular Disease in Elderly Patients
por: Strandberg, Timo E.
Publicado: (2019)

NAFLD and cardiovascular diseases: a clinical review
por: Kasper, Philipp, et al.
Publicado: (2020)

Prediction of advanced fibrosis in non-alcoholic fatty liver disease using gut microbiota-based approaches compared with simple non-invasive tools
por: Lang, Sonja, et al.
Publicado: (2020)

Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases
por: Yamashita, Shizuya, et al.
Publicado: (2020)

RNA Silencing in the Management of Dyslipidemias
por: Henney, Neil C., et al.
Publicado: (2021)

Elevated liver fibrosis index FIB-4 is not reliable for HCC risk stratification in predominantly non-Asian CHB patients
por: Demir, Münevver, et al.
Publicado: (2016)

Management of decompensated liver cirrhosis in the surgical intensive care unit
por: Kasper, Philipp, et al.
Publicado: (2023)

Current Role of Lipoprotein Apheresis
por: Thompson, Gilbert, et al.
Publicado: (2019)

Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD
por: Taskinen, Marja-Riitta, et al.
Publicado: (2019)

Can non-invasively detected liver fibrosis using serum-based scores really improve risk stratification in patients with acute coronary syndrome?
por: Steffen, Hans-Michael, et al.
Publicado: (2023)

Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels?
por: Cicero, Arrigo F. G., et al.
Publicado: (2021)

Use of statins after liver transplantation is associated with improved survival: results of a nationwide study
por: Becchetti, Chiara, et al.
Publicado: (2022)

Rare Treatments for Rare Dyslipidemias: New Perspectives in the Treatment of Homozygous Familial Hypercholesterolemia (HoFH) and Familial Chylomicronemia Syndrome (FCS)
por: D’Erasmo, Laura, et al.
Publicado: (2021)

Niacin Alternatives for Dyslipidemia: Fool’s Gold or Gold Mine? Part II: Novel Niacin Mimetics
por: Goel, Harsh, et al.
Publicado: (2016)

Niacin Alternatives for Dyslipidemia: Fool’s Gold or Gold Mine? Part I: Alternative Niacin Regimens
por: Dunbar, Richard L., et al.
Publicado: (2016)

Prognostic assessment of liver cirrhosis and its complications: current concepts and future perspectives
por: Gülcicegi, Dilan Elcin, et al.
Publicado: (2023)

Genetic Contribution to Non-alcoholic Fatty Liver Disease and Prognostic Implications
por: Martin, Katherine, et al.
Publicado: (2021)

Perinatal Obesity Induces Hepatic Growth Restriction with Increased DNA Damage Response, Senescence, and Dysregulated Igf-1-Akt-Foxo1 Signaling in Male Offspring of Obese Mice
por: Kasper, Philipp, et al.
Publicado: (2022)

Comparison of the relationships of alcoholic and nonalcoholic fatty liver with hypertension, diabetes mellitus, and dyslipidemia
por: Toshikuni, Nobuyuki, et al.
Publicado: (2013)

Non-alcoholic fatty liver disease (NAFLD) is associated with an increased incidence of chronic kidney disease (CKD)
por: Roderburg, Christoph, et al.
Publicado: (2023)

Targeted Temperature Management for Treatment of Cardiac Arrest
por: Rasmussen, Tyler P., et al.
Publicado: (2020)

Hepatocyte Mitochondrial Dynamics and Bioenergetics in Obesity-Related Non-Alcoholic Fatty Liver Disease
por: Legaki, Aigli-Ioanna, et al.
Publicado: (2022)

Acute Alcohol-Associated Hepatitis in the COVID-19 Pandemic — a Structured Review
por: Schulz, Philipp, et al.
Publicado: (2022)

Understanding the Assumptions Underlying Instrumental Variable Analyses: a Brief Review of Falsification Strategies and Related Tools
por: Labrecque, Jeremy, et al.
Publicado: (2018)

High Protein Intake Is Associated With Histological Disease Activity in Patients With NAFLD
por: Lang, Sonja, et al.
Publicado: (2020)

New perspective on type 2 diabetes, dyslipidemia and non‐alcoholic fatty liver disease
por: Matsuzaka, Takashi, et al.
Publicado: (2020)

Genetic Factors Influencing Drug-Induced Liver Injury: Do They Have a Role in Prevention and Diagnosis?
por: Clare, Kathleen E., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_rdt4gosssn8kvojgle5aaagiq6